- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03689660
Feasibility of Virtual Reality in Children With Neuromuscular Disease, Effectiveness of Virtual Reality and Biofeedback
June 16, 2022 updated by: Merve Kurt
The Feasibility of Virtual Reality in Children With Neuromuscular Disease and the Effectiveness of Virtual Reality and Biofeedback Training on Functional Levels of Children With Neuromuscular Disease
Our study is a randomized controlled study and the subjects included in the study will be divided into three groups as virtual reality training, biofeedback training, and conventional rehabilitation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
We have 3 purposes:
- Determine the feasibility of virtual reality training in children with neuromuscular disease.
- To determine the effect of virtual reality, biofeedback training, and conventional rehabilitation on functional levels and balances of children with neuromuscular disease.
- To compare the motivation of children with neuromuscular disease to virtual reality, biofeedback training, and conventional rehabilitation.
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Merve Kurt
- Phone Number: +90 5537241324
- Email: merveekurtt93@gmail.com
Study Contact Backup
- Name: Tülay Tarsuslu Şimşek
- Phone Number: 2324124923
- Email: tulay_tarsuslu@yahoo.com
Study Locations
-
-
Balcova
-
Izmir, Balcova, Turkey, 35340
- Recruiting
- Dokuz Eylül University
-
Contact:
- Tülay Tarsuslu Simsek, Prof.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 16 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Volunteer to participate in the study
- Being diagnosed with the neuromuscular disease
- No other systemic or neurological disease
- No significant visual or auditory loss
- Continuation of ambulation (10 m walking independently)
- Be able to understand simple commands
Exclusion Criteria:
- Performing a drug change at 3 months before treatment or during treatment which may affect muscle strength
- Acute inflammation in the musculoskeletal system
- Finding any orthopedic problem that prevents activities during the research
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Virtual Reality Training
Virtual reality treatment will be applied during the 12 weeks.
The training will consist of three sessions per week and 30 minutes per session.
|
Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
|
Experimental: Biofeedback Training
Biofeedback training will be applied during the 12 weeks.
The training will consist of three sessions per week and 30 minutes per session.
|
biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session.
Training will last 12 weeks.
|
Other: Conventional Rehabilitation
Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center.
If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
|
Participants will receive a 12-week conventional rehabilitation program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Motor Function Measure-32
Time Frame: 30 minutes
|
MFM-32 is a scale developed to evaluate motor functions of children and adults with neuromuscular disease.
The scale can be used to evaluate both in children with and without walking problems.The MFM-32 consists of 32 items.
Each item is answered with a 4-point likert scale (0 = cannot initiate the exercise or maintain its starting position, 1 = partially completes the exercise, 2 = completes exercises with compensations, slowly or roughly, 3 = completes the exercise in the standard pattern).
The scale can be used for the evaluation of individuals aged between 6 and 60 years.
|
30 minutes
|
Pediatric Functional Independence Measure
Time Frame: 5 minutes
|
WeeFIM consists of 18 items divided into 6 sub-scales (self-care, sphincter control, mobility, locomotion, communication, social communication).
Each item is scored from 1 to 7. A higher score indicates a better functional level.
|
5 minutes
|
Balance Master System
Time Frame: 20 minutes
|
The static and dynamic balance evaluated using the Balance Master System ver.
8.1.
(NeuroCom International Inc. Clackamas, OR, USA) force platform system which has multiple testing protocols designed to examine balance.
The system includes a computer linked force plate that records data with the aid of crystal transducers.
|
20 minutes
|
Vignos Scale
Time Frame: 2 Minutes
|
The Vignos Scale has been developed to evaluate the lower extremity functions.
The scale allows the lower extremity functions to be scored between 1 (can walk and climb stairs without help) and -10 (bed dependent).
|
2 Minutes
|
Feasibility of Virtual Reality
Time Frame: 1 Minutes
|
The feasibility of virtual reality will be examined by laboratory tests.
Laboratory tests to be carried out are as follows: Creatine Kinase, Lactate Dehydrogenase (LDH), Myoglobin, Serum Electrolytes, C-Reactive Protein levels.
These are agents that are indicative of muscle destruction or inflammation.
Will be evaluated in order to follow muscle destruction.
|
1 Minutes
|
Pediatric Motivation Scale
Time Frame: 5 Minutes
|
The PMOT is recommended for assessing motivation to rehabilitation program in children aged 8 to 18 years.
It comprises six subscales (effort-importance, interest-enjoyment, competence, relatedness, autonomy, and value-usefulness) with total 21 items.
While the 19 items of the scale are answered with a 6-point smiley face scale (1 = absolutely false, 6 = absolutely correct), there are 2 open-ended questions on the scale.
The high scores in each sub-scales indicate that the child's motivation in that sub-section is high.
A higher total score indicates that the motivation is intrinsically arranged and that the child has a high motivation.
From this point of view, the scale gives information about both the type of motivation and the amount of motivation of the child.
|
5 Minutes
|
Visual Analog Scale
Time Frame: 1 Minute
|
Visual Analog Scale will be applied to evaluate muscle pain.
It has a fixed line between two end adjectives of 100 mm length.
The end adjectives in our study will be "no pain" and "too much pain".
|
1 Minute
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pediatric Functional Reaching Test
Time Frame: 1 Minute
|
For the Pediatric Functional Reach test, children will be asked to raise their arms 90o in an upright posture position, extending to the maximum possible distance in three directions, forward, right, and left.
Reach distances will be measured by pointing the wall with the end point of the third finger, and distances; "start", "final" and "difference" will be determined in cm using tape measure.
|
1 Minute
|
Fall Frequency
Time Frame: 1 Minute
|
The frequency of the fall will be questioned with a chart created by the researchers.
The family will be asked to record the children's each fall a week before the study and a week after the treatment.
|
1 Minute
|
Muscle Strength Test with Hand Held Dinamometer
Time Frame: 20 minutes
|
Upper and lower limb muscles strength will be evaluated with hand held dinamometer device.
This device allows recording of muscle strength in kilograms.
|
20 minutes
|
Timed Up Go Test
Time Frame: 2 Minutes
|
For the time up go test, children will be asked to walk with two walking cones at a distance of 10 meters, at normal walking speeds, and the elapsed time will be recorded in seconds.
|
2 Minutes
|
Stair Climb Test
Time Frame: 2 Minutes
|
Children will be asked to climb up and down as quickly as they can, without running the steps, on a ladder of 16-20 cm height and 8-14 steps and the elapsed time will be recorded in seconds.
|
2 Minutes
|
T-shirt Wear Remove Test
Time Frame: 2 Minutes
|
For the T-shirt pull-out test, the children will be asked to wear a T-Shirt in the sitting position as soon as possible and the elapsed time will be recorded in seconds; then they will be asked to remove the T-Shirt as soon as possible and the elapsed time will be recorded in seconds.
|
2 Minutes
|
Stand Up from Supine Position Test
Time Frame: 1 Minutes
|
From the supine position to stand up, children will be asked to lie on the back of the body, the arms next to the body, the legs as closed as possible, and the head on the midline on a mat.
Then, from this position, they will be asked to stand as soon as possible and the elapsed time will be recorded in seconds.
|
1 Minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Tülay Tarsuslu Şimşek, Professor Dr.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2019
Primary Completion (Anticipated)
May 1, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
September 26, 2018
First Submitted That Met QC Criteria
September 26, 2018
First Posted (Actual)
September 28, 2018
Study Record Updates
Last Update Posted (Actual)
June 22, 2022
Last Update Submitted That Met QC Criteria
June 16, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Musculoskeletal Diseases
- Muscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Spinal Cord Diseases
- Muscular Disorders, Atrophic
- Motor Neuron Disease
- Muscular Dystrophies
- Muscular Atrophy
- Atrophy
- Muscular Dystrophy, Duchenne
- Muscular Atrophy, Spinal
- Neuromuscular Diseases
Other Study ID Numbers
- Merve Kurt
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
The IPD may share when requested
IPD Sharing Time Frame
IPD: Balance results, Functional Level, Diagnosis, demographic data
IPD Sharing Access Criteria
The IPD may share when requested.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
Clinical Trials on Virtual Reality Training
-
University of California, Los AngelesSuspendedDepression | Mood Disorders | Anhedonia | Stress | Anxiety | Virtual RealityUnited States
-
Riphah International UniversityCompleted
-
Luzerner KantonsspitalRecruitingParkinson DiseaseSwitzerland
-
IRCCS Eugenio MedeaUniversidad de Burgos; Asociatia Bucuresti Pentru Copii Dislexici; Augumented...Completed
-
Universidade do Oeste PaulistaUnknownCardiovascular Diseases | Body CompositionBrazil
-
Indiana UniversityCompletedAdolescent | Child | Attention Deficit and Disruptive Behavior Disorders | Conduct Disorder | Magnetic Resonance Imaging | Virtual Reality | Child Behavior Disorders | Social PerceptionUnited States
-
TOPMEDConseil de recherches en sciences naturelles et en génie du Canada; SEC Fonds...Recruiting
-
Vanderbilt UniversityUniversity of California, San DiegoCompleted
-
University of California, Los AngelesRecruiting
-
Mental Health Services in the Capital Region, DenmarkRigshospitalet, Denmark; University of Copenhagen; TrygFonden, DenmarkRecruitingDepression | Psychotic Disorders | Schizophrenia | Cognitive Impairment | Bipolar Disorder | Schizotypal DisorderDenmark